Femoral Fractures
Conditions
Brief summary
Supracondylar femur fractures in the geriatric population present a unique challenge to the orthopaedic surgeon both in terms of fixation, healing, and final extremity axial alignment. Pulsed dosing of parathyroid hormone derivatives (Forteo) has been shown to increase bone mass, and several studies in Europe have demonstrated its benefit as an adjuvant for fracture healing. Abaloparatide represents a new compound which similarly offers great potential for accelerating fracture healing, especially healing associated with callous formation. This is a randomized, double blind placebo-controlled trial to compare a group of patients being treated for supracondylar distal femur fractures who receive abaloparatide (n=38) with a control group of patients who receive a placebo (n=38).
Detailed description
Supracondylar femur fractures in the geriatric population present a unique challenge to the orthopaedic surgeon both in terms of fixation, healing, and final extremity axial alignment. Multiple methods of fixation are well accepted, and each has its own advantages and disadvantages. The common occurrence of periprosthetic supracondylar femur fractures adds another level of complexity, and the universal goal when treating these patients is to obtain and maintain acceptable alignment, allow mobilization and early weight bearing, and achieve union. To a degree, mobilization and weight bearing compete with maintenance of axial alignment, and any final outcome is a race between healing and loss of fixation. As a result, any intervention that can accelerate healing would be of great benefit. As the vast majority of these injuries heal with secondary bone healing (callous), the determination of healing is reliably determined using the modified Radiographic Union Score for Tibia Fractures (mRUST), and thus this patient population offers an ideal population in which to evaluate an accelerant of fracture healing. Pulsed dosing of parathyroid hormone derivatives (Forteo) has been shown to increase bone mass, and several studies in Europe have demonstrated its benefit as an adjuvant for fracture healing. Abaloparatide represents a new compound which similarly offers great potential for accelerating fracture healing, especially healing associated with callous formation. This is a randomized, double blind placebo-controlled trial to compare a group of patients being treated for supracondylar distal femur fractures who receive abaloparatide (n=38) with a control group of patients who receive a placebo (n=38).
Interventions
DRUGAbaloparatide
Abaloparatide will be dispensed as a 30-day supply of disposable pen injections of the standard, FDA approved dosage (80 mcg abaloparatide).
DRUGPlacebo
Placebo will be dispensed as a 30-day supply of disposable pen injections.
Sponsors
Radius Health, Inc.
Daniel Horwitz
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Subject is ≥ 65 years old 2. Subject is willing and able to read, comprehend, and sign the study informed consent form in English prior to study specific procedure 3. Subject is being treated for a closed supracondylar distal femur fracture with either a retrograde nail or locked plate 4. Subject undergoes open reduction/fixation
Exclusion criteria
1. Subject has open fracture 2. Bilateral injury or other lower extremity injury that would affect weight bearing status 3. Subject's postoperative radiographs (on day of surgery) indicate failure to achieve axial alignment (more than 10 degrees axial alignment and more than 25% anterior/posterior displacement in lateral view) 4. Subject has additional severe traumatic conditions such as closed head injury 5. Subject has medical condition or is on medication that may significantly affect healing (i.e. immunosuppressive diseases and drugs) 6. Subject has active or history of Paget's disease of the bone, bone cancer, or other bone diseases or conditions placing them at increased risk of osteosarcoma 7. Subject has active or history of hypercalcemia or underlying hypercalcemic disorder, such as primary hyperparathyroidism 8. Subject has active or a history of urolithiasis 9. Subject will have trouble injecting the pen and does not have someone to help them on a daily basis
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| modified Radiographic Union Score for Tibia Fractures (mRUST) | 6 weeks | degree of callous formation and healing (worst 4 - 16 best) |
| maintenance of axial alignment and loss of fixation | 6 weeks | change in the angle between the surface and fixed implant from the baseline radiographs (taken immediately postoperative) and the radiographs taken at 6, 12, and 24 weeks postoperative |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| modified Radiographic Union Score for Tibia Fractures (mRUST) | 12 weeks | degree of callous formation and healing (worst 4 - 16 best) |
| maintenance of axial alignment and loss of fixation | 12 weeks | change in the angle between the surface and fixed implant from the baseline radiographs |
Countries
United States
Outcome results
None listed